Remifentanil and droperidol administration for monitored anaesthesia care

Basit Öğe Kaydı
dc.contributor.authorKararmaz A.
dc.contributor.authorKaya S.
dc.contributor.authorTurhano?lu S.
dc.contributor.authorÖzyilmaz M.A.
dc.contributor.authorBayhan N.
dc.date.accessioned2024-04-24T17:58:42Z
dc.date.available2024-04-24T17:58:42Z
dc.date.issued2002
dc.departmentDicle Üniversitesien_US
dc.description.abstractIn this prospective randomised study, it was aimed to evaluate which dose of remifentanil applied via patient controlled analgesia (PCA) was proper for monitored anaesthesia care during extracorporeal shock wave lithotripsy in patients received droperidol as pretreatment [A1]. Droperidol (20 ?g/kg) was administered intravenously, and then the subjects were randomly assigned to one of three groups. Group I (n=20) received a remifentanil 1 ?g/kg as loading and bolus dose and infusion of 0.01 ?g/kg/min; Group II (n=20) received a remifentanil 0.5 ?g/kg as loading and bolus dose and infusion of 0.05 ?g/kg/min; Group III (n=20) received a remifentanil 0.1 ?g/kg as loading and bolus dose and infusion of 0.1 ?g/kg/min. Two minutes after applying loading dose with PCA, ESWL procedure was started. Hemodynamic and respiratory data, adverse effects such as nausea, vomiting, dizziness, level of pain and sedation were recorded. The end of ESWL procedure, consumption of remifentanil was recorded. After satisfactions of patients were registered, the patients fully recovered discharged from hospital. In Group I and Group II, level of pain was significantly lower than Group III (p<0.05). In Group I, frequency of respiratory and hemodynamic depression was higher than other group. However, In Group III, incidences of nausea, vomiting and dizziness were higher than other group. Satisfactions of patients were statistically highest in Group II. Moreover, consumption of remifentanil was lowest in Group II. No difference was among three group in discharge time from hospital. We concluded that for monitored anaesthesia care during ESWL, remifentanil at loading and bolus dose of 0.5 ?g/kg and infusion rate of 0.05 ?g/kg/min provided effective analgesia and had low incidence of adverse effects in patients had been received droperidol.en_US
dc.identifier.endpage172en_US
dc.identifier.issn1016-5150
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-0036338931en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage167en_US
dc.identifier.urihttps://hdl.handle.net/11468/24062
dc.identifier.volume30en_US
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.relation.ispartofTurk Anesteziyoloji ve Reanimasyonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDroperidolen_US
dc.subjectEswlen_US
dc.subjectMonitored Anaesthesia Careen_US
dc.subjectRemifentanilen_US
dc.titleRemifentanil and droperidol administration for monitored anaesthesia careen_US
dc.title.alternativeMonitorize Anestezi Bakimi İçin droperidol ve remifentanil kullanimien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu